China Pharmaceutical Distributor—Redefining the Future of Healthcare Supply Chain
The healthcare system in China is undergoing rapid transformation, and the China pharmaceutical distributor is…
Articles
China’s First Homegrown ADC for HER2-Mutant NSCLC Approved—Trastuzumab Rezetecan Injection Officially Launched
The National Medical Products Administration (NMPA) has officially approved the Class 1 innovative drug Trastuzumab…
The Path to Excellence for a Hong Kong Pharmaceutical Distributor: Quality, Compliance and Traceability
In the critical world of healthcare procurement, the choice of a pharmaceutical distributor is a…
Innovative Drugs List 2025 in China 丨 Insights into the China Drug Market and the Rise of Drugs Made in China
The China drug market—once known mainly for its generics and large-scale manufacturing—has evolved into a…
Beyond Price: How to Mitigate Risks and Identify Reliable China Pharmacy Wholesale Suppliers in 2025
In the rapidly evolving global healthcare landscape, China pharmacy wholesale suppliers are playing an increasingly…
Unlocking Global Markets: A Comprehensive Analysis of China Pharmaceutical Import and Export Wholesalers
Within the global pharmaceutical industry chain and supply network, China is evolving from the “World’s…
Chinese Innovative Drugs Surge Ahead: Fosun Pharma’s License-Out Deals Exceed USD 60 Billion
Source: DengYueMed On October 18, Chen Yuqing, Chairman of Fosun Pharma, stated at an event…
China’s Pharmaceutical Breakthroughs Go Global: Behind the $45 Billion Boom and the Next Great Test
China’s Pharmaceutical Innovation Goes Global: Challenges and New Momentum In the first five months of…
Breaking free from pharmaceutical tariffs! Can innovative drugs accelerate overseas expansion by 2025?
On May 6, the U.S. government announced plans to unveil new pharmaceutical tariff measures within…
Top 10 China Pharma Deals 2025: $40B in Global Innovation Exports
In the first half of 2025, China’s innovative drug license-out deals surpassed USD 15 billion,…